Clinical Trials DEA Policy Therapy 
Cannabis Law Report
OCTOBER 4, 2021
Advanced Illness , Oregon Psilocybin Advisory Board , Oregon Psilocybin Services Act , Psilocybin , Psilocybin Therapy , Psychedelics , Right To Try. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.
Veriheal
JUNE 30, 2023
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. Clinical Trials and Human Subject Protections.
Cannabis Law Report
FEBRUARY 28, 2022
Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 10 × 10. See, e.g., Jennifer M. Mitchell et al., Divito & Robert F.
Canna Law Blog
NOVEMBER 6, 2021
But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. The following year, President Richard Nixon declared drug abuse public enemy number one, and in 1973, he formed the Drug Enforcement Administration (DEA).
Cannabis Law Report
APRIL 8, 2022
as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D.,
Canna Law Blog
MARCH 4, 2020
In an even larger trend, the health care provider community seems to be exploring various alternative therapies and emerging medicines to improve quality of care. The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.
Expert insights. Personalized for you.
52 
Let's personalize your content